Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Candistat is a brand name for a line of azole antifungal medications, primarily encompassing formulations of **itraconazole** and **miconazole**. As a systemic treatment, the itraconazole capsule formulation is utilized for a variety of fungal infections, including blastomycosis, histoplasmosis, aspergillosis, and onychomycosis. It functions by inhibiting the fungal cytochrome P450-dependent enzyme 14α-demethylase (encoded by the CYP51A1 gene), which is critical for the biosynthesis of ergosterol. The resulting depletion of ergosterol and accumulation of methylated sterol precursors lead to the disruption of fungal cell membrane structure and function. Additionally, Candistat is marketed as a topical cream containing miconazole for the treatment of superficial fungal skin infections. The brand is primarily distributed in specific international markets, such as the Philippines, by manufacturers like Unilab.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Candistat.